Labetuzumab Y-90

Drug Profile

Labetuzumab Y-90

Alternative Names: Anti-CEA monoclonal antibody MN 14-Y-90; CEA-Cide-Y-90; hCEA-Y-90; IMMU-101

Latest Information Update: 19 Jan 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Immunomedics
  • Class Antineoplastics; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer; Colorectal cancer; Pancreatic cancer

Most Recent Events

  • 23 Jun 2004 Immunomedics has completed two phase I trials in colorectal and pancreatic cancers in the US
  • 23 Apr 2002 Phase-I/II clinical trials in Colorectal cancer in USA (IV-infusion)
  • 23 Apr 2002 Phase-I/II clinical trials in Pancreatic cancer in USA (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top